DALLAS, Texas – Patients are now enrolling in the Texas Multi-Cancer Early Detection (MCED) Program, a collaboration that brings together Baylor Scott & White Research Institute and Exact Sciences Corp.as part of the Falcon Registry study: Exact Sciences MCED Real-World Evidence Registry.
With an aim of intercepting cancers in Texans earlier, when treatment may be more effective, the program includes approximately 50,000 Multi-Cancer Early Detection (MCED) tests being administered to patients across North Texas from diverse racial, social and geographic backgrounds, including urban and rural areas. As part of the Falcon Registry study, the Exact Sciences MCED test will be used to complement standard screening methods enabling the potential for earlier-stage cancer detection, which can be associated with higher rates of survival and positive patient outcomes.
"This is a whole new era in which we can detect cancers even before a scan, giving us a chance to intercept cancer earlier than ever before," said Ronan Kelly, MD, MBA, FASCO, director of oncology, Baylor Scott & White Charles A. Sammons Cancer Center at Baylor University Medical Center at Dallas, and chief of oncology, North Texas Division, Baylor Scott & White Health. Dr. Kelly leads the Texas MCED program and is the principal investigator of the broader Falcon Registry Real-World Evidence study.
"The U.S. government's Cancer Moonshot initiative calls for a decrease in cancer mortality by 50% over the next 25 years, and major cancer centers and health systems like ours are ready to take on this challenge," said Dr. Kelly. "As the largest not-for-profit integrated healthcare delivery network in Texas, Baylor Scott & White is poised and ready to help with this national effort."
About Baylor Scott & White Health
As the largest not-for-profit health system in the state of Texas, Baylor Scott & White promotes the health and well-being of every individual, family and community it serves. It is committed to making quality care more accessible, convenient and affordable through its integrated delivery network, which includes the Baylor Scott & White Health Plan, Baylor Scott & White Research Institute, the Baylor Scott & White Quality Alliance and its leading digital health platform – MyBSWHealth. Through 51 hospitals and more than 1,200 access points, including flagship academic medical centers in Dallas, Fort Worth and Temple, the system offers the full continuum of care, from primary to award-winning specialty care. Founded as a Christian ministry of healing more than a century ago, Baylor Scott & White today serves more than three million Texans. For more information, visit BSWHealth.com.
About Exact Sciences Corp.
A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier. Building on the success of the Cologuard® and Oncotype® tests, Exact Sciences is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis. For more information, visit ExactSciences.com, follow Exact Sciences on X (formerly known as Twitter) @ExactSciences, or find Exact Sciences on LinkedIn and Facebook. Oncotype is a registered trademark of Genomic Health, Inc. Exact Sciences and Cologuard are registered trademarks of Exact Sciences Corporation. All other trademarks and service marks are the property of their respective owners.
# # #
